Preliminary Study on Pulse Wave Changes in Patients with Inflammatory Arthropathies Treated with bDMARDs

Michela Gasparotto, Giuliano Di Pierro, Barbara Toffoli, Andrea Grillo, Marco Bressan, Marco Fiorentin, Lorenzo Di Luozzo, Fabio Fischetti, Margherita Zen, Bruno Fabris, Stella Bernardi, Paola TomiettoJournal of Clinical Medicine 2024 · DOI

TL;DR

This study investigated how pulse wave parameters, indicators of arterial stiffness and cardiovascular risk, change in patients with inflammatory arthropathies treated with biologic disease-modifying drugs (bDMARDs). The findings suggest that bDMARD therapy can improve arterial stiffness in some inflammatory arthritis patients (AS and RA), but not in others (PsA), highlighting potential differences in cardiovascular risk profiles and treatment responses.

What Problem Does This Paper Address?

Patients with inflammatory arthropathies, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA), face a significantly higher risk of cardiovascular disease (CVD) compared to the general population. This increased risk is not always adequately captured by traditional CVD risk scores. Systemic inflammation in these conditions accelerates atherosclerosis and promotes arterial stiffening, contributing to higher morbidity and mortality. While bDMARDs have shown promise in reducing overall CVD risk, the specific impact on vascular health, particularly arterial stiffness, remains an area needing further quantification. Pulse wave parameters, like carotid-femoral pulse wave velocity (cfPWV), are known predictors of CVD risk and can provide a more nuanced assessment of vascular health. This paper aims to evaluate how these pulse wave parameters change in patients with inflammatory arthropathies before and after bDMARD therapy.

Methods

The researchers conducted an observational prospective study involving adult patients diagnosed with RA, AS, or PsA who were prescribed bDMARD therapy. Pulse wave parameters were measured using applanation tonometry, a non-invasive technique, at two time points: at the start of bDMARD therapy (T0) and after 24 months (T24). Key pulse wave parameters assessed included:

  • Carotid-femoral pulse wave velocity (cfPWV): A gold-standard measure of aortic stiffness.
  • Augmentation index (AIx): Reflects pulse wave reflection and aortic stiffness.
  • Subendocardial viability ratio (SEVR): An indicator of cardiac perfusion and coronary reserve.
  • Left ventricular ejection time (LVET): Related to left ventricular systolic function.
  • Central systolic (SBPc) and diastolic (DBPc) blood pressure: Blood pressure within the heart and aorta.
  • Systolic slope (SysS): May indicate vascular stenosis.

In addition to pulse wave analysis, patients underwent clinical assessments (including disease activity scores like BASDAI, HAQ-DI, TJC, SJC, PGA) and laboratory tests (CRP, ESR, lipid profile, cytokines). Statistical analyses included univariate correlations (Pearson/Spearman), group comparisons (t-test/Wilcoxon, ANOVA/Kruskal-Wallis), and multivariate linear regression to identify independent predictors of pulse wave parameters. Longitudinal changes were analyzed using the Wilcoxon matched pairs signed rank test.

Datasets

The study utilized data collected from 36 adult patients with inflammatory arthropathies (16 AS, 10 PsA, 10 RA) recruited from the Rheumatology Unit of Cattinara Teaching Hospital between January 2019 and December 2021. No new datasets were introduced; the study relied on patient data collected prospectively.

Key Insights and Ideas

  • Age is a primary driver of arterial stiffness: The study strongly confirms that increasing age is independently associated with unfavorable pulse wave parameters, including increased central systolic blood pressure (SBPc) and higher cfPWV. This aligns with the well-established link between aging and vascular stiffening.
  • Chronic damage impacts cardiac perfusion: Higher scores on the Health Assessment Questionnaire Disability Index (HAQ-DI), a measure of functional status and disability, were independently associated with lower SEVR. This suggests that long-term disease burden and functional impairment can negatively affect myocardial oxygen supply and demand.
  • OPG as a potential CVD risk marker: Osteoprotegerin (OPG) levels showed a univariate association with increased cfPWV and SBPc. While this association didn't hold up in multivariate analysis, it supports the growing evidence that OPG may play a role in cardiovascular risk, possibly through mechanisms like promoting vascular calcification.
  • PsA patients present with higher baseline stiffness: Notably, patients with psoriatic arthritis (PsA) exhibited higher baseline cfPWV compared to those with AS and RA. This finding, coupled with a higher proportion of male subjects and slightly elevated CRP in the PsA group, suggests a potentially more compromised vascular profile at the outset.
  • Differential response to bDMARDs: The most significant insight is the differential effect of bDMARD therapy on pulse wave parameters across the disease groups. While AS and RA patients showed improvements in certain parameters (indicating better vascular health), PsA patients did not exhibit significant changes in their pulse wave parameters after two years of treatment.

Key Results

  • Baseline associations:
    • cfPWV was significantly associated with age (p < 0.001).
  • SEVR was negatively associated with C-reactive protein (CRP) (p = 0.04) and HAQ-DI (p = 0.03).
  • PsA patients had a higher percentage of male subjects, higher CRP, and the highest cfPWV values at baseline (p = 0.048).
  • Longitudinal changes after 2 years of bDMARD therapy:
    • AS patients: Showed a significant increase in SEVR (p = 0.027) and a reduction in SysS.
  • RA patients: Exhibited a significant decrease in SBPc (p = 0.023), AIx (p = 0.027), and LVET (p = 0.02).
  • PsA patients: Showed no significant changes in pulse wave parameters.
  • Disease activity improvements: Despite no vascular changes, PsA patients showed significant improvements in disease activity markers (CRP, TJC, SJC, PGA, BASDAI). AS patients also showed significant reductions in CRP and SJC.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small sample size: The study included only 36 patients, which limits the statistical power and generalizability of the findings.
  • Heterogeneity: The cohort comprised patients with different types of inflammatory arthropathies, varying clinical and demographic characteristics, and diverse bDMARD treatments.
  • Lack of a control group: The study did not include a healthy control group or a group with inflammatory arthropathies not receiving bDMARDs for direct comparison of baseline vascular health.

Future work should focus on:

  • Larger cohorts: Replicating these findings in larger, more homogeneous patient groups is crucial.
  • Longer follow-up periods: Extending the follow-up beyond two years could reveal delayed vascular changes or long-term trends.
  • Specific bDMARD effects: Investigating whether different classes or specific bDMARDs have varying impacts on arterial stiffness.
  • Understanding PsA differences: Further research is needed to elucidate why PsA patients show a less favorable response in terms of vascular parameters, potentially exploring genetic factors, different inflammatory pathways, or a higher baseline CVD risk profile.

Summary updated

Abstract

<b>Background:</b> Patients with inflammatory arthropathies exhibit an increased cardiovascular disease (CVD) risk as compared to the general population, which is not fully quantified by the conventional CVD risk scores. Biotechnological disease-modifying drugs (bDMARDs) have proved beneficial to reduce the overall CVD risk in these patients, although CVD remains a major cause of increased mortality. Since it has been shown that pulse wave parameters and in particular carotid-femoral pulse wave velocity (cfPWV) are predictors of CVD risk, the aim of this study was to evaluate their changes in patients with inflammatory arthropathies before and after bDMARD therapy. <b>Methods:</b> Pulse wave parameters were evaluated with applanation tonometry in patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA), and rheumatoid arthritis (RA), before and after two years of bDMARD therapy. <b>Results:</b> At baseline, cfPWV was significantly associated with age (<i>p</i> < 0.001) and, among pulse wave parameters, the subendocardial viability ratio was negatively associated with C-reactive protein (CRP) (<i>p</i> = 0.04) and the HAQ-disability index (<i>p</i> = 0.03). At baseline, PsA patients showed a higher percentage of male subjects, higher CRP, and the highest cfPWV values (<i>p</i> = 0.048). After two years, pulse wave parameters improved in the AS and RA groups, but not in the PsA group. <b>Conclusions:</b> Our data confirm that pulse wave parameters are potentially reversible after bDMARD therapy, as they improved in AS and RA patients. In PsA patients, there were no changes, which may be due to the higher percentage of male subjects and higher baseline cfPWV values.
BibTeX
@article{gasparotto2024preliminary,
  author = {Michela Gasparotto and Giuliano Di Pierro and Barbara Toffoli and Andrea Grillo and Marco Bressan and Marco Fiorentin and Lorenzo Di Luozzo and Fabio Fischetti and Margherita Zen and Bruno Fabris and Stella Bernardi and Paola Tomietto},
  title = {{Preliminary Study on Pulse Wave Changes in Patients with Inflammatory Arthropathies Treated with bDMARDs}},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  doi = {10.3390/jcm13092684},
}
Figure